{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:55:55Z","timestamp":1792425355126,"version":"4.5.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Crohn's and Colitis"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.crohns.2012.05.012","type":"journal-article","created":{"date-parts":[[2012,6,5]],"date-time":"2012-06-05T17:17:15Z","timestamp":1338916635000},"page":"208-212","source":"Crossref","is-referenced-by-count":85,"title":["Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening"],"prefix":"10.1093","volume":"7","author":[{"given":"Aranzazu","family":"Jauregui-Amezaga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Turon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Ord\u00e1s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Gallego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faust","family":"Feu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ricart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juli\u00e1n","family":"Pan\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"10.1016\/j.crohns.2012.05.012_bb0005","series-title":"WHO Report 2011","author":"Global Tuberculosis Control","year":"2011"},{"key":"10.1016\/j.crohns.2012.05.012_bb0010","series-title":"Tuberculosis Surveillance Report 2009. European Centre for Disease Prevention and Control. Regional Office for Europe","year":"2009"},{"key":"10.1016\/j.crohns.2012.05.012_bb0015","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2174\/138945010790309902","article-title":"Mucosal healing and anti TNFs in IBD","volume":"11","author":"Van Assche","year":"2010","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.crohns.2012.05.012_bb0020","unstructured":"Infliximab approval process in Crohn's disease. Deparment of Health and Human Services. Public Health Service. Food and Drug Administration August 24, 1998."},{"key":"10.1016\/j.crohns.2012.05.012_bb0025","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.crohns.2012.05.012_bb0030","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/0092-8674(89)90676-4","article-title":"The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection","volume":"56","author":"Kindler","year":"1989","journal-title":"Cell"},{"key":"10.1016\/j.crohns.2012.05.012_bb0035","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/1074-7613(95)90001-2","article-title":"Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice","volume":"2","author":"Flynn","year":"1995","journal-title":"Immunity"},{"key":"10.1016\/j.crohns.2012.05.012_bb0040","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.4049\/jimmunol.168.9.4620","article-title":"TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection","volume":"168","author":"Roach","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.crohns.2012.05.012_bb0045","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/art.11137","article-title":"Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report","volume":"48","author":"Gomez-Reino","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.crohns.2012.05.012_bb0050","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/art.21043","article-title":"Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists","volume":"52","author":"Carmona","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.crohns.2012.05.012_bb0055","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1157\/13042212","article-title":"Consensus guideline on tuberculosis and treatment of inflammatory bowel disease with infliximab. Spanish Working Group on Crohn Disease and Ulcerative Colitis","volume":"26","author":"Obrador","year":"2003","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.crohns.2012.05.012_bb0060","first-page":"81","article-title":"Recommendations on tuberculosis and treatment of inflammatory bowel disease with infliximab. 2006 update","volume":"29","author":"Lopez-San Roman","year":"2006","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.crohns.2012.05.012_bb0065","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.crohns.2012.05.012_bb0070","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn's disease","volume":"350","author":"Sands","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.crohns.2012.05.012_bb0075","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.crohns.2012.05.012_bb0080","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2012.05.012_bb0085","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2012.05.012_bb0090","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa062897","article-title":"Maintenance therapy with certolizumab pegol for Crohn's disease","volume":"357","author":"Schreiber","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.crohns.2012.05.012_bb0095","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.gastro.2003.10.047","article-title":"The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients","volume":"126","author":"Colombel","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2012.05.012_bb0100","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1136\/gut.2008.163642","article-title":"Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study","volume":"58","author":"Fidder","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2012.05.012_bb0105","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.autrev.2008.07.011","article-title":"Screening for tuberculosis infection prior to initiation of anti-TNF therapy","volume":"8","author":"Lalvani","year":"2008","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.crohns.2012.05.012_bb0110","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.eimc.2009.05.012","article-title":"Interferon gamma release assays: principles and practice","volume":"28","author":"Lalvani","year":"2010","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.crohns.2012.05.012_bb0115","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/ibd.21427","article-title":"Factors impacting the results of interferon-gamma release assay and tuberculin skin test in routine screening for latent tuberculosis in patients with inflammatory bowel diseases","volume":"17","author":"Papay","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2012.05.012_bb0120","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1111\/j.1572-0241.2008.02050.x","article-title":"Comparison of interferon-gamma release assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease","volume":"103","author":"Schoepfer","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2012.05.012_bb0125","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/S0140-6736(06)68579-6","article-title":"Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study","volume":"367","author":"Ferrara","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.crohns.2012.05.012_bb0130","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1378\/chest.08-2575","article-title":"Performance of tests for latent tuberculosis in different groups of immunocompromised patients","volume":"136","author":"Richeldi","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.crohns.2012.05.012_bb0135","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/ard.2007.070789","article-title":"Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon gamma assay","volume":"67","author":"Matulis","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.crohns.2012.05.012_bb0140","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/ibd.21329","article-title":"QuantiFERON TB gold testing for tuberculosis screening in an inflammatory bowel disease cohort in the United States","volume":"17","author":"Qumseya","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2012.05.012_bb0145","first-page":"1","article-title":"Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection\u2014United States, 2010","volume":"59","author":"Mazurek","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.crohns.2012.05.012_bb0150","series-title":"Interferon-gamma release assays testing versus tuberculosis skin testing for tuberculosis: a review of the clinical effectiveness and guidelines. Rapid response report 2011","year":"2011"},{"key":"10.1016\/j.crohns.2012.05.012_bb0155","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.crohns.2009.02.010","article-title":"European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease","volume":"3","author":"Rahier","year":"2009","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.crohns.2012.05.012_bb0160","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.arbres.2010.02.010","article-title":"Consensus document on the diagnosis, treatment and prevention of tuberculosis","volume":"46","author":"Gonzalez-Martin","year":"2010","journal-title":"Arch Bronconeumol"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1873994612002346?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1873994612002346?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/7\/3\/208\/1106627\/7-3-208.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,22]],"date-time":"2017-08-22T17:57:02Z","timestamp":1503424622000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-lookup\/doi\/10.1016\/j.crohns.2012.05.012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S1873994612002346"],"URL":"https:\/\/doi.org\/10.1016\/j.crohns.2012.05.012","relation":{},"ISSN":["1873-9946"],"issn-type":[{"value":"1873-9946","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}